bevacizumab


Also found in: Thesaurus, Medical, Wikipedia.

bev·a·ciz·u·mab

 (bĕv′ə-sĭz′ə-măb′)
n.
A humanized monoclonal antibody that acts as an angiogenesis inhibitor, used intravenously to treat metastatic colorectal cancer and certain other types of cancer.

[beva-, origin unknown + -ci-, cardiovascular infix + -zu-, humanized + -m(onoclonal) a(nti)b(ody).]
References in periodicals archive ?
VBL Therapeutics reported top-line results from its pivotal Phase 3 GLOBE study in patients with recurrent glioblastoma which was designed to evaluate VB-111 in combination with bevacizumab, compared to the bevacizumab control arm.
A new study published in Mayo Clinic Proceedings provides good quality evidence for the excellent safety profile and efficacy of intravenous bevacizumab in the management of these patients.
MVASI is the first biosimilar bevacizumab approved by the EC, and is approved in combination with fluoropyrimidine-based chemotherapy for metastatic carcinoma of the colon or rectum; in combination with paclitaxel for metastatic breast cancer.
MVASI is reportedly the first biosimilar bevacizumab approved by the EC.
This study was planned to determine the incidence of endophthalmitis after office-based intravitreal bevacizumab injection and to compare it with previously reported incidence of endophthalmitis after operation theatre-based intravitreal injections.
The manufacturing of Russian biosimilars of rituximab and bevacizumab indicated for the treatment of cancer will be based in Morocco.
Objective: To study the outcomes of intravitreal injection of Bevacizumab and laser photocoagulation in the treatment of diabetic macular edema (DME).
There are various anti-VEGF medications available on the market, bevacizumab (Avastin, Genentech, San Francisco, USA) being the predominant one in Croatia.
Objectives: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration.
Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report
New data from Boehringer Ingelheim's Phase IINVICTAN-1 study show that BI 695502, its bevacizumab biosimilar candidate, is bioequivalent to Roche's Avastin, an angiogenesis inhibitor used to treat a variety of cancers and marketed in the U.
Objective: To compare the effect of intravitreal triamcinolone (IVT) alone with combined intravitreal triamcinolone (IVT) and intravitreal bevacizumab (IVB) on central macular thickness (CMT) in patients of diabetic macular edema (DME).